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The development of blue or gray cutaneoushyperpigmentation is a rare complication of
chronic imipramine therapy.1,2 Treatment options
for imipramine-induced hyperpigmentation are
limited but include topical retinoids, bleaching
agents, and laser therapy, with varying degrees of
success.3 We report a case in which Q-switched
alexandrite laser therapy alone led to nearly com-
plete resolution of imipramine-induced dyspigmen-
tation in a patient who had been taking this
medication for 4 decades. Paradoxical darkening of
imipramine-induced hyperpigmentation after
combined Q-switched neodymium-doped yttrium
aluminum garnet (Nd:YAG) and Q-switched ruby
laser therapy has recently been demonstrated.4 Here,
we further report a similar pattern of focal
paradoxical hyperpigmentation after treatment of
imipramine-induced hyperpigmentation with
Q-switched alexandrite laser therapy that resolved
with additional treatment sessions.
Hyperpigmentation is a rare side effect of chronic
tricyclic antidepressant use characterized by
progressive blue or slate-gray dyspigmentation
primarily affecting sun-exposed sites. Complexes of
melanin with a drug metabolite are found within
dermal macrophages and free in the dermis.1
Dyspigmentation may resolve spontaneously if the
offending medication is withdrawn. There is a single
previous case report of successful treatment of
imipramine-induced dyspigmentation with a combi-
nation of therapies including carbon dioxide and
erbium YAG (Er:YAG) laser resurfacing, topical
hydroquinone, a topical retinoid, topical
vitamin C serum, and Q-switched ruby and
alexandrite lasers.3 In addition, Izikson and
Anderson recently reported paradoxical darkening
after combined Q-switched Nd:YAG and ruby laser
therapy in another patient with imipramine-induced
hyperpigmentation.4
Case Report
A 66-year-old woman presented to our laser clinic
with a 4- to 5-year history of progressive
blue–brown discoloration of her face and neck and
the dorsal surfaces of her hands (Figure 1). She has a
history of depression for which she had taken
imipramine daily for 40 years, and she noticed the
discoloration soon after initiating hormone replace-
ment therapy (HRT) for menopausal symptoms. She
discontinued HRT but was unwilling to consider
discontinuing imipramine, and the dyspigmentation
gradually progressed, ultimately leading to social
withdrawal. On physical examination, she had
diffuse, striking, macular blue–brown to purple
hyperpigmentation of her face, neck, and upper
chest, with less-pronounced involvement of the
dorsal hands. A biopsy was performed at her lateral
neck, demonstrating golden-brown pigmented
material within tissue macrophages and free in the
dermis consistent with medication-induced hyper-
pigmentation (Figure 2).
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Initial test spot laser treatments of right-sided
preauricular skin performed with Q-switched
Nd:YAG, Q-switched frequency-doubled Nd:YAG,
and Q-switched alexandrite lasers demonstrated the
most significant improvement with the last.
Quadrants of the patient’s facial skin and neck were
subsequently treated with the Q-switched alexand-
rite laser (spot size 2–3 mm, fluence 8–10 J/cm2) on
four occasions over a 6-month period, with marked
clearing of treated skin (Figure 3). After three treat-
ments, several dark blue macules measuring 2 to
3 mm in diameter were noted in focal areas along the
left jaw line and temple. The sites of paradoxical
darkening resolved after treatment with additional
Q-switched alexandrite laser therapy. The patient is
currently scheduled to undergo similar treatment of
the affected areas of her hands. After clinical
resolution of the hyperpigmentation, our patient’s
psychological status improved substantially, and she
and her husband report that she has been able to
return to her normal social activities (Figure 4).
Given our patient’s resistance to discontinuing
imipramine, she will probably require further laser
treatments in the future to maintain the strikingFigure 1. Preoperative appearance of the patient’s facial skin
demonstrating marked blue–brown hyperpigmentation.
Figure 2. Sections demonstrate an unremarkable epidermis.
In the superficial and mid-dermis are small collections of
golden-brown pigmented material within tissue macro-
phages and free in the dermis. The pigmentary deposits
are consistent with drug-induced pigmentation.
Figure 3. Clinical improvement with clearance of pigmen-
tation on the right side of the face. Note the contrast be-
tween the patient’s normal skin color and that of untreated
skin on the right side of the neck and at the hairline.
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improvement already seen, but there has been no
recurrent dyspigmentation of the face for 1 year.
Discussion
A variety of medications may produce cutaneous
dyspigmentation. The successful use of Q-switched
laser therapy has been reported in the treatment of
drug-induced hyperpigmentation from the use of
minocycline, amiodarone, phenothiazines, and
tricyclic antidepressants.5–7 Clearance of imipra-
mine-induced hyperpigmentation using Q-switched
alexandrite laser treatments as monotherapy has not
previously been described. Our patient had a marked
response to this laser therapy despite the fact that she
remained on imipramine throughout her treatment
series and had taken this medication for approxi-
mately 40 years. We believe that this is the longest
duration of drug use in the fewer than 20 cases of
imipramine-induced hyperpigmentation reported in
the literature.
Although the precise etiology of imipramine-induced
hyperpigmentation is not known, drug metabolites
are believed to deposit in the skin, possibly com-
plexed with melanin. The obvious photodistribution
of our patient’s hyperpigmentation supports the
theory of photoactivation of the imipramine metab-
olites in producing the clinically apparent dyspig-
mentation. The 755-nm-wavelength Q-switched
alexandrite laser may provide optimal correction of
imipramine-induced hyperpigmentation not only
because the melanin–drug metabolite complex is a
chromophore for light of this wavelength, but also
because the alexandrite laser produces light that
penetrates well into the dermis, where even deeply
located pigment may be selectively targeted.
Finally, although our patient experienced focal areas
of paradoxical macular darkening soon after begin-
ning her treatment series, this responded completely
to additional Q-switched alexandrite laser therapy
using slightly higher fluences. The cause of this
phenomenon is unclear, but we can speculate that the
initial laser treatments chemically altered but did not
destroy the pigment and that subsequent exposure to
higher-fluence laser energy may have resulted in
complete photothermolysis. Given that there was no
paradoxical darkening in more than 99% of the
treated skin’s surface area, we would propose that
treating physicians observe for this phenomenon but
that the possibility of its occurrence is not a con-
traindication to the use of this device. We believe
that Q-switched alexandrite laser therapy may cur-
rently be considered the treatment of choice for
imipramine-induced hyperpigmentation.
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